Zydus Lifesciences Faces Setback In US Litigation With Japan Firm

Zydus Lifesciences on Wednesday announced that a US district court has issued an order against the company in a patent litigation case involving Japanese firm Astellas Pharma Inc. The case pertains to the validity of a patent held by Astellas, the company stated in an exchange filing

The litigation involved a sustained-release formulation of mirabegron, which is marketed in the US by Astellas Pharma under the brand name Myrbetriq. Mirabegron is used to treat an overactive urinary bladder, the company said.